Proton therapy safer than older radiotherapies for esophageal cancer
the ONA take:
According to new researcher presented at the annual conference of the Particle Therapy Cooperative Group in San Diego, California, researchers from the University of Maryland School of Medicine in Baltimore have found that patients with esophageal cancer treated with proton therapy experienced significantly fewer adverse events than patients treated with conventional radiation therapies.
For the study, researchers identified about 600 patients with esophageal cancer and found that proton therapy was associated with significantly fewer incidents of nausea, blood abnormalities, and loss of appetite than older radiation therapies.
Proton therapy has shown efficacy in various types of cancer, including brain, breast, esophageal, head and neck, liver, lung, prostate, and spinal cord cancers. It is expected that up to 30% of patients with cancer will benefit from targeted proton beam therapy, which can precisely target tumors while reducing radiation to healthy issue.
"This evidence underscores the precision of proton therapy, and how it can really make a difference in cancer patients' lives," said Michael Chuong, MD, an assistant professor of radiation oncology at the University of Maryland School of Medicine.
Patients with esophageal cancer treated with proton therapy experienced significantly fewer adverse events.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- Breast Conservation Improves Survival vs Mastectomy in Breast Cancer
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Affect of Daratumumab on Laboratory Blood Test Results
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|